After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device industries. He has written about Covid-19 vaccines, advances in cancer treatments, ...
Upfront and milestone payments offset weak COVID-19 vaccine demand CEO John Jacobs says licensing strategy insulates Novavax from policy uncertainty C. difficile vaccine candidate to enter trials by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results